secwatch.observer — SEC 8-K summary
======================================

Issuer:     Biomea Fusion, Inc. (BMEA)
CIK:        0001840439
Form:       8-K
Filed at:   2025-10-06T23:59:59+00:00
Accession:  0001193125-25-231903
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Biomea Fusion reports 52-week Phase II COVALENT-111 data: HbA1c reductions up to 1.5% in severe insulin-deficient T2D
--------------------------------------------------------------------------------

- In severe insulin-deficient T2D patients (n=10), icovamenib achieved durable HbA1c reduction of 1.2% (p=0.01) through Week 52 after 12 weeks dosing.
- Best result in Arm B (n=6): mean HbA1c reduction of 1.5% (p=0.01); no treatment-related serious adverse events.
- In patients on GLP-1 therapy not at glycemic targets (n=11), icovamenib added 1.3% HbA1c reduction (p=0.05) sustained to Week 52.
- Phase IIb trial (COVALENT-211) in severe insulin-deficient T2D expected to start Q4 2025; Phase II with GLP-1 (COVALENT-212) also Q4.
- Food Effect Study (COVALENT-121) ongoing, expected completion by December 2025; oral GLP-1 RA (BMF-650) Phase I data anticipated H1 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840439/000119312525231903/0001193125-25-231903-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840439/000119312525231903/d79150d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-231903

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer